Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB6B | ISIN: US26818M1080 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:59
9,580 US-Dollar
-4,96 % -0,500
1-Jahres-Chart
DYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiJones Trading initiates Dyne Therapeutics stock with buy rating1
MiJones Trading startet Dyne Therapeutics-Aktienabdeckung mit Kaufempfehlung1
18.06.H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock2
17.06.Dyne falls amid delay in clinical program for muscle disorder therapy2
17.06.Dyne Therapeutics stock falls after updated plan for accelerated approval in DM11
DYNE THERAPEUTICS Aktie jetzt für 0€ handeln
17.06.Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint322WASHINGTON (dpa-AFX) - Dyne Therapeutics (DYN) announced the FDA has granted Breakthrough Therapy Designation to DYNE-101 for the treatment of myotonic dystrophy type 1. The company also announced...
► Artikel lesen
17.06.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting106- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase...
► Artikel lesen
17.06.Dyne Therapeutics, Inc. - 8-K, Current Report3
05.06.Dyne Therapeutics, Inc. - 8-K, Current Report3
05.06.Dyne Therapeutics, Inc.: Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress-
02.06.Oppenheimer assumes Dyne Therapeutics stock at outperform, PT $341
13.05.Stifel maintains Buy on Dyne stock with $66 target post-meeting1
08.05.Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates391WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361...
► Artikel lesen
08.05.Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights268- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE...
► Artikel lesen
08.05.Dyne Therapeutics, Inc. - 8-K, Current Report6
08.05.Dyne Therapeutics, Inc. - 10-Q, Quarterly Report3
25.04.EC grants orphan drug designation to Dyne Therapeutics' DMD therapy2
24.04.Dyne Therapeutics-Aktie steigt nach Erhalt des Orphan-Drug-Status1
24.04.Dyne Therapeutics stock rises on orphan drug status1
24.04.EC grants orphan drug status to Dyne's DMD treatment3
Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1